SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q4 2024 earnings on February 20, 2025. The consensus estimate for Q4 2024 revenue is $59.12 million, and the earnings are expected to ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

SpringWorks Therapeutics (NASDAQ:SWTX) jumped 10% in premarket trading after the firm reported its Q4 results and canceled ...

Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product ...

$SWTX insiders have traded $SWTX stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.

Wedbush increased their Q2 2025 earnings per share estimates for SpringWorks Therapeutics in a research report issued on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the ...

For SWTX (NASDAQ:SWTX), we notice a call option trade that happens to be bearish, expiring in 7 day(s) on February 21, 2025. This event was a transfer of 50 contract(s) at a $50.00 strike.

Wall Street expects a year-over-year increase in earnings on higher revenues when SpringWorks Therapeutics (SWTX) reports results for the quarter ended December 2024. While this widely-known ...

Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...

SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...

In this article, we are going to take a look at where SpringWorks Therapeutics Inc. (NASDAQ:SWTX) stands against the other ...

Looking at options history for SpringWorks Therapeutics (NASDAQ:SWTX) we detected 68 trades. If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened ...